Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.

Montañez-Wiscovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA.

Oncogene. 2009 Oct 15;28(41):3608-18. doi: 10.1038/onc.2009.221. Epub 2009 Aug 3.


Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells.

Montañez-Wiscovich ME, Shelton MD, Seachrist DD, Lozada KL, Johnson E, Miedler JD, Abdul-Karim FW, Visvader JE, Keri RA.

J Pathol. 2010 Nov;222(3):271-81. doi: 10.1002/path.2762.


Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer.

Sum EY, Segara D, Duscio B, Bath ML, Field AS, Sutherland RL, Lindeman GJ, Visvader JE.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64. Epub 2005 May 16.


The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells.

Yue L, Li L, Liu F, Hu N, Zhang W, Bai X, Li Y, Zhang Y, Fu L, Zhang X, Ye L.

Carcinogenesis. 2013 Apr;34(4):927-35. doi: 10.1093/carcin/bgs399. Epub 2013 Jan 5.


ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL.

Cancer Res. 2001 Sep 1;61(17):6583-91.


Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.

Zhang Q, Sakamoto K, Liu C, Triplett AA, Lin WC, Rui H, Wagner KU.

Cancer Res. 2011 Dec 15;71(24):7513-24. doi: 10.1158/0008-5472.CAN-11-1783. Epub 2011 Oct 28.


ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.

Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL.

Mol Cell Biol. 2002 Apr;22(7):2204-19.


The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer.

Visvader JE, Venter D, Hahm K, Santamaria M, Sum EY, O'Reilly L, White D, Williams R, Armes J, Lindeman GJ.

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7.


Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation.

Yu M, Lin G, Arshadi N, Kalatskaya I, Xue B, Haider S, Nguyen F, Boutros PC, Elson A, Muthuswamy LB, Tonks NK, Muthuswamy SK.

Mol Cell Biol. 2012 Oct;32(19):3913-24. doi: 10.1128/MCB.00068-12. Epub 2012 Jul 30.


ErbB2 down-regulates microRNA-205 in breast cancer.

Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T.

Biochem Biophys Res Commun. 2011 Aug 12;411(4):804-8. doi: 10.1016/j.bbrc.2011.07.033. Epub 2011 Jul 20.


PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells.

Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, Lu KP.

Mol Cell Biol. 2002 Aug;22(15):5281-95.


HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM.

Cell Death Dis. 2014 Jan 2;5:e980. doi: 10.1038/cddis.2013.508.


The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells.

Wang N, Lin KK, Lu Z, Lam KS, Newton R, Xu X, Yu Z, Gill GN, Andersen B.

Oncogene. 2007 Sep 27;26(44):6431-41. Epub 2007 Apr 23.


ErbB2 induces Notch1 activity and function in breast cancer cells.

Lindsay J, Jiao X, Sakamaki T, Casimiro MC, Shirley LA, Tran TH, Ju X, Liu M, Li Z, Wang C, Katiyar S, Rao M, Allen KG, Glazer RI, Ge C, Stanley P, Lisanti MP, Rui H, Pestell RG.

Clin Transl Sci. 2008 Sep;1(2):107-15. doi: 10.1111/j.1752-8062.2008.00041.x.


p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.

Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.

Cancer Res. 2006 May 1;66(9):4672-80.


Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.

Worthington J, Bertani M, Chan HL, Gerrits B, Timms JF.

BMC Cancer. 2010 Sep 14;10:490. doi: 10.1186/1471-2407-10-490.


Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.

Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, Gregg JP, Cardiff RD, Borowsky AD, Sweeney C, Carraway KL 3rd.

Cancer Res. 2006 Dec 1;66(23):11279-86.


Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein.

Singh RR, Barnes CJ, Talukder AH, Fuqua SA, Kumar R.

Cancer Res. 2005 Nov 15;65(22):10594-601.


FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.

Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, Zheng P, Liu Y.

J Clin Invest. 2007 Dec;117(12):3765-73.

Items per page

Supplemental Content

Support Center